Topic Archives: antiviral

Comments

  • Avatar

    There is at least one trial already underway to see if antiviral medication can help with Alzheimer's, given the discove...

  • Avatar

    $$CYDY VANCOUVER, Washington, Feb. 20, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) reports the successful achiev...

  • JohnM

    Michael - for your flu article, look at Rapivab, the only IV flu antiviral approved for use in the ICU. Lots of children...

  • JohnM

    $Casey & ER, your post should be required reading for Gummies AND potential ER docs. I know from friends that this flu h...

  • Dr. KSS MD PhD

    Zimmy.....yes absolutely, and likely by recruitment of TLR's as well (Toll like receptors, ever sniffing for nucleic aci...

  • Avatar

    $THIS and $THAT $WEED.TO, $POT, $MJ $TRPX np :) Abstract: Cannabinoid receptors type 1 (CB1) and type 2 (CB2) ha...

  • Avatar

    $CWBR $Antiviral $Mitochondria dysfunction Hi, Belgiumchocolate: A couple of recent (2017) medical papers may he...

  • Avatar

    $CWBR $COB.U , FP Hi fellow Gummies, I was doing some DD this weekend and here is just a thought I wanted to share...

  • SoGiAm

    $ABVX - Evotec and ABIVAX enter into strategic collaboration to develop novel antiviral agents https://www.evotec.com/a...

  • Avatar

    $RGLS - of interest is language in the 8-K that expands on the problems associated with the clinical hold on RG- 101 and...

  • Dr. KSS MD PhD

    Sorry, yes it is ABX-464. Other than parking in the stock, which I have done, I have to admit I don't have a sense of cl...

  • Avatar

    $CYDY abstract Abstract Title: Interim Results of PRO 140 in a Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients...

  • Avatar

    $ABVX Has anyone commented on this alternative explanation for the ABIVAX HIV viral reservoir effect: "The explana...

  • Dr. KSS MD PhD

    Redsox/Peter: To continue musing about Abivax, let me make what I think is an important point. In the early days of t...

  • Avatar

    $noticker Dr. Julius Youngner, Polio Vaccine Pioneer, Dies at 96 "Dr. Youngner was the last surviving member of the or...

  • Avatar

    $ABVX full link in English: http://www.abivax.com/en/news-events/press-releases/479-first-ever-evidence-of-treatment-in...

  • Dr. KSS MD PhD

    I'm not coming down on you, but I gotta say I am just shocked that you would seriously wield an "analysis" of ContraVir ...

  • Avatar

    12-Apr-2017:06:07:00, Novan Reports Positive Topline Results with SB208 in Phase 2 TrialClinical Evidence of Antifungal ...

  • Avatar

    I have a small position in Abivax. An article published in Retrovirology, 2015, presented an alternative explanation for...

  • Dr. KSS MD PhD

    New evidence of an increasingly bulked up, entrained and sophisticated biotech industry in Taiwan, long with the scienti...

  • Avatar

    If you like Nano-particles....there are many places to invest . NanoViricides, Inc. (NNVC) is using them as an antivira...

  • Avatar

    $GILD $RGLS W #HCV #HCC #TumorEnvironment *Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Vi...

  • Dr. KSS MD PhD

    This article willfully misleads, Alley. First, it's trying to depict its agent as a prodrug of tenofovir and implies Gil...

  • Avatar

    $RGLS On Wednesday the NYT published, "Are New Drugs for Hepatitis C Safe? A Report Raises Concerns: https://www.nyt...

  • Avatar

    A phase 1b of RG-101 was published in The Lancet recently: "Safety, tolerability, and antiviral effect of RG-101 in p...

  • Avatar

    This abstract more than likely moving RGLS of late. Background and aims: MicroRNA (miR)-122 is the most abundant mi...

  • Avatar

    $GILD Very interesting... Here we describe a patient with advanced follicular lymphoma and concurrent hepatitis C vi...

  • Avatar

    Would like to present a company here that has been on a tear the last 5 days and has 2 drugs targeting HEP B and shingle...

  • Avatar

    $ARWR $AMGN #HBV - An interesting article published this morning "Arrowhead: Two Collaborations in One Week" Rece...

  • SoGiAm

    $ARWR np - Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1...

  • Avatar

    'twas me that asked you the question! And after reading your opinion, I shall scratch it off my watch list forthwith. Th...

  • JohnM

    $PTN - I don't believe the conspiracy theory that Feuerstein shorts stocks and then writes about them. But I do think a ...

  • Avatar

    There was a piece on ReachMD some years back when it was on XM satellite about a researcher at LSU who was going out wit...

  • JohnM

    $BCRX BioCryst has an approved antiviral that knocks out swine, bird, Zika and most flus in the ICU. Also approved in Ja...

  • Dr. KSS MD PhD

    Tough but not mean. My rules wouldn't apply in your case as you're being legitimately rx'd a controlled substance, which...

  • sogiam

    $ARWR - Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress(TM) 20...

  • Dr. KSS MD PhD

    Yes, agree, 18 months is a very long time when the virus in question is a labile RNA virus. Not an eternity, but certain...

  • sogiam

    From France, a Phase II HIV Antiviral with Promising Results #ABX464 #Abivax #CGIB: https://t.co/Z6TrnC6Pe5 image: h...

  • Avatar

    A small Australian company Nanosonics (ASX:NAN) has developed infection control/ decontamination procedure for ultrasoun...

  • Avatar

    Thought this may be of interest to some. Stock rose just over 120% today. ContraVir Pharmaceuticals, Inc. (NASDAQ: CTR...

  • Dr. KSS MD PhD

    Arrowhead's HBV data is out for single doses. Somewhat as expected the antiviral efficacy is not as high as I would've l...

  • sogiam

    ARWR- Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate AR...

  • JohnM

    There is a portion of the virus that is conserved during its mutations. Otherwise, it ceases to be a virus. By targeting...

  • Gui_

    TLOG starting over: The company intends to initiate a combination single ascending dose/multiple ascending dose clin...

  • Dr. KSS, MD PhD

    I tend to doubt we will see MERS action here. First, half of all South Korean cases are traceable to one facility. Next,...

  • Avatar

    $INO: FWIW: Doc KSS comments were "prospects are so bad I have a hard time seeing how it can continue at all". Somehow I...

  • Avatar

    FYI even dirk has turned on Benitec... http://www.biocqr.com/#!rss-feeds/c2t8 Time is running out for Benitec Benite...

  • Patricia

    Well Cyndy, I think you'd agree that we need both natural healing agents AND modern pharmaceuticals! I think the problem...

  • Dr. KSS, MD, PhD

    Hi Stephen: There just isn't clinical evidence that vitamin D use leads to coronary calcification. It's been looked for...

  • Avatar

    Robert - Re PETX – (Aratana Therapeutics ) Chart looks like it starting to form a “cup and handle” pattern. It ha...

  • DBMD

    Since January 2014, a total of 1107 patients have started antiviral treatment. Among genotype 1 patients, 60% were treat...

  • Avatar

    CMRX - Chimerix This is a nice chart. From 14 to 35 in the last year. Working on an Ebola treatment. Chimerix's ...

  • Dr. KSS, MD PhD

    So they studied a mere 34 patients with mild disease, and this makes it into NEJM? Very dismaying. An Interferon-fr...

  • Avatar

    SA Breaking News (Sunday 5:06 pm): Achillion presents HCV data at The Liver Meeting • 5:06 PM At this week's Annual ...

  • Dr. KSS, MD PhD

    It's a fair question...about $ARWR. I got hold of the abstract on 8 October. Michael Yee of RBC Capital or one of his as...

  • Dr. KSS, MD PhD

    Duncan's surviving son and brother contend in their suit against the Dallas hospital that Duncan received no form of inv...

  • Avatar

    Dr. KSS and fellow gummies - an interesting presentation by the UC San Diego AntiViral Research Center on infectious dis...

  • Dr. KSS, MD PhD

    William...yes, what you are describing is a customary angle on antiviral drug design, A "silent mutation" isn't really s...

  • Avatar

    Doc KSS or anyone who may have stumbled across this; Have you ever heard of or what do you know about REPLICor? htt...

  • Dr. KSS, MD PhD

    Doesn't matter.....this is for the old form of tenofovir: TDF. The newer form, TAF, has better antiviral activity and pe...

  • JohnM

    Thank you, Dr. KSS. I think you are exactly right on. I am holding BioCryst (BCRX), but not for its Ebola antiviral....

  • Dr. KSS, MD PhD

    To Jack Weiss: I am in no way a supporter of milkthistle/silymarin use. It is not that it has not been proven to be of b...

  • Dr. KSS, MD PhD

    Hi Doug: glad you are here and thanks for posting. Stick around. It's hard for me to see NNVC ever going anywhere. It...

  • Dr. KSS, MD PhD

    KennyG: I have taken to completely ignoring Pannobhaso because he gets so very much so very wrong. The Tribetarna trial ...

  • Dr. KSS, MD PhD

    Here's an interesting situation: NovaBay Pharm (NBY) is a $40 million company in California that is developing a novel c...

  • JohnM

    Dr, KSS - RE Marburg and Ebola, BioCryst (BIOC) has an antiviral for most (all?) hemmoraigic fevers in animal trials. No...

  • Avatar

    I believe the truth is somewhere between the medical doctors who belittle alternative or complimentary health care, and ...

  • Dr. KSS, MD PhD

    Diana: to me that is definitely a risk. And while chlorination is reasonably antibacterial, its antifungal and antiviral...

  • Avatar

    HEB's Aferon(R) N shows anti-MERS activity in vitro. http://www.investorvillage.com/smbd.asp?mb=270&mn=232&pt=msg&mid=1...

  • Dr. KSS, MD PhD

    Frank: there are some physician message boards, and just during the weekend, hints are being dropped that Alferon has be...

  • Avatar

    gumshoegabby: I agree; the most successful antiviral therapy is immunizations; the problem is how to help the body find ...

  • Avatar

    FYI: LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical comp...

  • Avatar

    I have no position but its nice to see the space get recognition. I have the full report but weary of posting. Arr...

  • Avatar

    This is a safety concern with the FDA (and EMEA) as there is no off switch. This is one reason why therapeutic vaccines ...

  • karmaswimswami

    Biocqr: Milkthistle is silymarin ("silly," get it?). I would not be caught dead recommending this nonsense and would ost...

  • karmaswimswami

    It is frankly difficult for me to get interested in NNVC (Nanoviricides). Its agents are sequestrants, partitioners. Vir...

  • Avatar

    I would be curious to hear KSS's take on NNVC... NanoViricides, Inc. (www.nanoviricides.com) is a development stage c...

  • karmaswimswami

    You are quite right George. In the days before DAA's for HCV, the single best and most potent interferon-alfa (consensus...

  • karmaswimswami

    JJ: Thanks for your comment. You are quite right about M. Graham. The specific guy who designed TT-034 with its three sh...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch